26CA Stock Overview
A clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
ImmunityBio, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$3.44 |
| 52 Week High | US$9.21 |
| 52 Week Low | US$1.17 |
| Beta | -0.34 |
| 11 Month Change | -2.55% |
| 3 Month Change | -40.92% |
| 1 Year Change | 116.48% |
| 33 Year Change | -59.23% |
| 5 Year Change | n/a |
| Change since IPO | -87.48% |
Recent News & Updates
Recent updates
Shareholder Returns
| 26CA | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 11.0% | 2.6% | 4.5% |
| 1Y | 116.5% | -16.4% | 13.4% |
Return vs Industry: 26CA exceeded the German Biotechs industry which returned -16.4% over the past year.
Return vs Market: 26CA exceeded the German Market which returned 13.4% over the past year.
Price Volatility
| 26CA volatility | |
|---|---|
| 26CA Average Weekly Movement | 9.2% |
| Biotechs Industry Average Movement | 6.2% |
| Market Average Movement | 5.0% |
| 10% most volatile stocks in DE Market | 11.6% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 26CA's share price has been volatile over the past 3 months.
Volatility Over Time: 26CA's weekly volatility has decreased from 17% to 9% over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 622 | Rich Adcock | immunitybio.com |
ImmunityBio, Inc., a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies. The company’s platforms have generated therapeutic agents that are currently being or planned to be studied in clinical trials across various indications in liquid and solid tumors, including bladder, lung and colorectal cancers, and glioblastoma multiforme.
ImmunityBio, Inc. Fundamentals Summary
| 26CA fundamental statistics | |
|---|---|
| Market cap | €2.45b |
| Earnings (TTM) | -€535.25m |
| Revenue (TTM) | €1.17m |
2,093x
P/S Ratio-4.6x
P/E RatioIs 26CA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 26CA income statement (TTM) | |
|---|---|
| Revenue | US$1.31m |
| Cost of Revenue | US$0 |
| Gross Profit | US$1.31m |
| Other Expenses | US$598.96m |
| Earnings | -US$597.65m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.86 |
| Gross Margin | 100.00% |
| Net Profit Margin | -45,691.67% |
| Debt/Equity Ratio | -137.1% |
How did 26CA perform over the long term?
See historical performance and comparison